Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Karl-Fredrik Eriksson

Associate professor

Default user image.

Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Author

  • Yang De Marinis
  • Torgny Sunnerhagen
  • Pradeep Bompada
  • Anna Bläckberg
  • Runtao Yang
  • Joel Svensson
  • Ola Ekström
  • Karl Fredrik Eriksson
  • Ola Hansson
  • Leif Groop
  • Isabel Gonçalves
  • Magnus Rasmussen

Summary, in English

The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.

Department/s

  • Genomics, Diabetes and Endocrinology
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Infection Medicine (BMC)
  • Translational infection medicine
  • Clinical Chemistry, Malmö
  • Division of Clinical Chemistry and Pharmacology
  • LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research
  • Cardiovascular Research - Translational Studies

Publishing year

2020

Language

English

Publication/Series

Infection Ecology and Epidemiology

Volume

10

Issue

1

Document type

Journal article

Publisher

Taylor & Francis

Topic

  • Infectious Medicine
  • Clinical Laboratory Medicine

Keywords

  • antibody test
  • COVID-19
  • disease severity and duration
  • IgM and IgG
  • SARS-CoV-2
  • serology assessment

Status

Published

Project

  • Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Research group

  • Genomics, Diabetes and Endocrinology
  • Translational infection medicine
  • Clinical Chemistry, Malmö
  • LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research
  • Cardiovascular Research - Translational Studies

ISBN/ISSN/Other

  • ISSN: 2000-8686